BiomX (PHGE) AI Stock Analysis

• Market Cap: $7.12M
• Dividend Yield: N/A
• Average Volume (3M): 1.32M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.47
• Revenue Growth: N/A
• EPS Growth: 54.25%
• Country: US
• Employees: 52
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 1,593,703
• 10 Day Avg. Volume: 1,108,900
• 30 Day Avg. Volume: 1,322,820
• PEG Ratio: 0.18
• Price to Book (P/B): -100.26
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.95
• Enterprise Value/Market Cap: 0.51
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -1.34
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: $26.00
• Price Target Upside: 481.66% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $4.50 ▲(0.67% Upside)
• Action: Reiterated Date: 02/20/26
• Date: Action: Reiterated 02/20/26

The score is primarily held down by weak financial performance (no revenue, persistent cash burn, and negative equity) and significant negative corporate developments (trial discontinuation and subsidiary insolvency). Technical indicators are neutral-to-slightly positive and provide limited support, while valuation metrics are constrained by negative earnings; earnings-call updates show clinical/regulatory progress but underscore near-term funding and execution risks.

Positive Factors

Proprietary phage platform

BiomX’s core proprietary phage discovery and engineering platform provides a durable competitive advantage in targeted antibacterial therapeutics. A platform approach supports multiple programs, repeatable R&D workflows, and potential partnering/licensing opportunities that can de-risk single-product exposure and sustain pipeline growth over years.

Regulatory clarity for BX011

Clear FDA guidance for BX011 materially reduces regulatory uncertainty and shortens development complexity. Eliminating additional nonclinical study requirements lowers incremental cost/time, improves the probability of a streamlined path to approval, and enhances the commercial viability of an off-the-shelf DFI product with dual-use defense market potential.

Enhanced governance and strategic investor support

The private placement and board expansion bring financial backing and experienced oversight, which are durable governance improvements. Independent board representation and a strategic investor can help drive better financing access, disciplined capital allocation, and stronger strategic planning, supporting execution across clinical milestones over the medium term.

Negative Factors

Weak balance sheet and negative equity

Persistent negative equity and a history of volatile leverage materially weaken the company’s financial resilience. A thin or negative capital cushion increases refinancing and counterparty risk, constrains negotiation leverage with partners, and raises the likelihood of further dilutive financings to fund ongoing clinical development.

Operational disruption from subsidiary insolvency

The insolvency and deconsolidation of the Israeli unit represent a structural operational setback: loss of operational control, potential asset forfeiture, management distraction, and disruption to clinical programs. This raises execution risk, could delay timelines, and complicates partnerships and regulatory interactions for programs previously managed through the subsidiary.

Short cash runway and reliance on dilutive financing

A limited cash runway (cash expected to fund operations only into Q1 2026) combined with reliance on short‑dated, high‑cost convertible preferreds and warrants increases refinancing and dilution risk. Such instruments can burden cash flow with dividends or force dilutive conversions, constraining long-term funding flexibility for clinical development.

BiomX Business Overview & Revenue Model

Company Description

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease; and BX003, an orally administered phage cocktail, which is in Phase 1b/2a that targets a bacterial target present in the gut of IBD and PSC patients. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

How the Company Makes Money

BiomX primarily makes money through research and development collaborations, grants, and potential future product sales. The company engages in partnerships with pharmaceutical and biotechnology companies to co-develop phage therapies, which can provide upfront payments, milestone payments, and royalties. Additionally, BiomX may receive funding from governmental or non-profit grants to support its research initiatives. As its products progress through clinical trials and potentially reach the market, revenue from sales of approved therapies will become a significant source of income.

BiomX Financial Statement Overview

Summary

Financial profile remains weak: no revenue, multi-year operating losses, and consistently negative operating/free cash flow. The 2025 net income swing does not translate into cash generation, and stockholders’ equity turning slightly negative in 2025 increases funding and financial-flexibility risk.

Income Statement

The income statement shows no revenue across the reported years, and operating results are consistently deeply negative (EBIT and EBITDA losses from 2020–2024). Net losses persist through 2024, indicating an ongoing burn-phase business model typical of early-stage biotech. While 2025 shows a sharp swing to positive net income, the lack of revenue and ongoing losses historically make earnings quality and sustainability difficult to underwrite, suggesting the profit is likely non-operating or one-time in nature based on the dataset provided.

Balance Sheet

Leverage has been volatile: debt rose meaningfully in prior years and the debt-to-equity profile deteriorated sharply in 2023, then improved in 2024 as equity was still positive. However, 2025 stands out negatively with stockholders’ equity turning slightly negative, which is a key balance-sheet risk signal (thin/negative capital cushion). Total debt is relatively low in 2025 versus prior years, but the negative equity position limits financial flexibility and can increase refinancing and funding risk.

Cash Flow

Cash generation is consistently weak with negative operating cash flow and negative free cash flow every year shown, pointing to continued reliance on external funding. Free cash flow also deteriorates in 2024 and further in 2025, and operating cash flow remains meaningfully negative despite the 2025 net income print—highlighting a disconnect between reported earnings and cash performance. Overall, cash burn remains the central financial risk.

Breakdown	Dec 2025	Dec 2024	Mar 2024	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-2.92M	-1.80M	-871.00K	0.00	0.00
EBITDA	-29.99M	-13.13M	-22.82M	-23.66M	-32.90M
Net Income	-36.20M	-17.73M	-26.17M	-28.32M	-36.23M
Balance Sheet
Total Assets	70.24M	43.23M	25.03M	45.53M	77.99M
Cash, Cash Equivalents and Short-Term Investments	4.96M	17.81M	14.91M	33.33M	62.10M
Total Debt	1.44M	9.58M	15.09M	19.36M	20.02M
Total Liabilities	71.54M	19.09M	21.95M	24.49M	30.45M
Stockholders Equity	-1.30M	24.15M	3.08M	21.04M	47.53M
Cash Flow
Free Cash Flow	-26.39M	-37.01M	-21.34M	-29.20M	-31.25M
Operating Cash Flow	-26.39M	-36.98M	-21.29M	-29.09M	-27.57M
Investing Cash Flow	108.00K	715.00K	1.95M	-2.11M	16.17M
Financing Cash Flow	13.19M	38.37M	2.90M	292.00K	37.28M

BiomX Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 4.47
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PHGE, the sentiment is Negative. The current price of 4.47 is below the 20-day moving average (MA) of 5.57, above the 50-day MA of 3.62, and below the 200-day MA of 7.59, indicating a neutral trend. The MACD of 0.35 indicates Positive momentum. The RSI at 47.47 is Neutral, neither overbought nor oversold. The STOCH value of 38.58 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PHGE.

BiomX Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LPCN	54 Neutral	$52.35M	-9.28	-32.92%	―	-44.31%	-34.17%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PHGE	45 Neutral	$7.12M	-0.19	-154.50%	―	―	54.25%
CANF	41 Neutral	$5.96M	―	―	―	―	―
IMRN	40 Underperform	$6.47M	-1.24	-49.00%	―	47.17%	26.84%

BiomX Corporate Events

BiomX Restructures After Insolvency and Executive Terminations

On December 8, 2025, BiomX Israel discontinued its Phase 2b clinical trial of nebulized phage therapy BX004 in cystic fibrosis patients and subsequently entered insolvency proceedings in Israel, with a court-appointed trustee taking control on January 25, 2026. Following the trustee’s termination of BiomX Ltd.’s officers on February 4, 2026, BiomX Inc. deemed this a change of control, deconsolidated the subsidiary as a significant asset disposition, and issued unaudited pro forma financials showing the impact of removing BiomX Israel from its balance sheet and results.

On February 4, 2026, BiomX Ltd.’s CEO Jonathan Solomon and CFO Marina Wolfson, and on February 9, 2026, Chief Development Officer Merav Bassan, were notified that their officer roles at BiomX Ltd. were terminated retroactive to January 25, 2026, though all three remain in their corresponding positions at BiomX Inc. The terminations triggered severance and notice-period obligations, underscoring a restructuring that shifts operational and financial control away from the insolvent Israeli unit while preserving the parent company’s executive leadership structure.

The most recent analyst rating on (PHGE) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Completes Private Placement and Board Expansion

On January 13, 2026, the company completed a previously announced private placement of its securities under a Securities Purchase Agreement dated December 26, 2025, and in connection with that closing expanded its board to nine members and appointed investment professional Reuven Yeganeh as an independent Class 1 director, with a term running until the 2027 annual meeting, subject to certain ownership conditions. Also on January 13, 2026, the company entered into a standard-form indemnification agreement with Yeganeh and filed a Certificate of Designations in Delaware establishing its Series Y Convertible Preferred Stock, issuing 3,300 preferred shares alongside warrants for common stock, a move that refines its capital structure and adds experienced financial oversight at the board level.

The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Subsidiary Terminates Maryland Facility Lease Agreement

On December 31, 2025, Adaptive Phage Therapeutics, LLC (APT), a wholly owned subsidiary of the Company, entered into a Seventh Amendment to its lease for premises in Gaithersburg, Maryland, resulting in the termination of the lease effective the same date. Under the settlement, APT agreed to a one-time payment of $800,000 and acknowledged the landlord’s draw on an existing letter of credit for $153,557.68, with the landlord agreeing, upon satisfaction of specified conditions, to release APT and the parent company from further obligations and liabilities under the lease, aside from limited surviving obligations, thereby resolving outstanding lease-related claims and closing out the company’s commitments at that facility.

The most recent analyst rating on (PHGE) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Announces New Preferred Stock Financing and Warrants

On December 26, 2025, BiomX Inc. entered into a Securities Purchase Agreement with a single investor for a private placement of 3,300 shares of newly created Series Y Convertible Preferred Stock, with an aggregate stated value of $3.3 million, and accompanying warrants to purchase 3,300,000 shares of common stock, for expected gross proceeds of $3.0 million before fees. The Series Y Preferred Stock carries a 15% annual dividend payable in cash or stock, ranks senior to common stock and existing Series X preferred stock, has a one-year maturity, and is initially convertible at $2.00 per share, while the warrants are immediately exercisable at $2.00 per share for five years, with both instruments subject to price adjustments and a 19.99% beneficial ownership cap until stockholder approval is obtained. As part of the deal, the investor secured board representation rights tied to ownership thresholds, BiomX committed to seek stockholder approval within 60 days to permit issuance of more than 19.99% of its outstanding common shares, and it granted registration rights for resale of the underlying securities, signaling a significant equity financing that could meaningfully dilute existing shareholders but strengthens the company’s balance sheet and brings in an influential strategic investor; H.C. Wainwright & Co. acted as exclusive placement agent and will receive fees and additional warrants, and the transaction is expected to close on or about December 30, 2025, subject to customary conditions.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Study and Files for Insolvency

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b study due to resource constraints, which led to the decision to file for insolvency proceedings for its Israeli subsidiary, BiomX Ltd. The company is now evaluating strategic options while maintaining its BX011 program for diabetic foot infections.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Discontinues Phase 2b Trial for BX004

On December 8, 2025, BiomX Inc. announced the discontinuation of its Phase 2b clinical trial for BX004, a treatment for Cystic Fibrosis associated with chronic Pseudomonas aeruginosa infections, due to resource constraints. The company is now focusing on advancing its bacteriophage-based therapeutics, particularly BX011 for diabetic foot infections, while also implementing cost-cutting measures and exploring strategic alternatives.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.

BiomX Updates on Phase 2b Study for BX004

On November 25, 2025, BiomX Inc. announced updates regarding its Phase 2b study of BX004 for Cystic Fibrosis treatment, which faced a clinical hold by the FDA due to concerns over a third-party nebulizer device. The company is actively working with the manufacturer to resolve these issues and anticipates resuming U.S. enrollment once resolved and financing is secured. Additionally, an independent Data Monitoring Committee recommended continuing the study with an adjusted dosing regimen after a safety review, with topline results expected in the second quarter of 2026, contingent on financial resources.

The most recent analyst rating on (PHGE) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on BiomX stock, see the PHGE Stock Forecast page.